NRAS and neoplasm: Indeed, of the 19 evaluable patients in our study whose tumor tissue analysis failed to reveal one of the seven aforementioned mutations in BRAF or NRAS, one patient (1/19, 5%) was found to have a circulating BRAF V600E mutation.